Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)

08/12/2021 | 05:09pm EDT

Item 8.01 Other Events.

On August 12, 2021, VYNE Therapeutics Inc. (the "Company") provided an update regarding its liquidity in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Additionally, the Company updated the disclosure in Note 1 of the consolidated financial statements from its Form 10-K for the year ended December 31, 2020 to add disclosure regarding liquidity and capital resources. The Company's independent registered public accounting firm reissued its report on the Company's audited consolidated financial statements as of December 31, 2020 and for the year then ended December 31, 2020 to include an emphasis of matter paragraph regarding liquidity and capital resources as discussed in Note 1 to the consolidated financial statements. The audited consolidated financial statements and the updated report is included as Exhibit 99.1 to this Current Report on Form 8-K. Other than as described in the preceding sentence, Exhibit 99.1 does not revise, modify, update or otherwise affect the audited consolidated financial statements.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits


The following exhibit is being filed herewith.



Exhibit No.  Description

  23.1         Consent of PricewaterhouseCoopers LLP

  23.2         Consent of Kesselman & Kesselman

  99.1         Audited Consolidated Financial Statements

             Cover Page Interactive Data File (embedded within the Inline XBRL
104          document)

© Edgar Online, source Glimpses

All news about VYNE THERAPEUTICS INC.
10/26Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm..
PU
10/26VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/26Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflamm..
AQ
10/21VYNE THERAPEUTICS : Announces Formation of Scientific Advisory Board
AQ
10/19VYNE THERAPEUTICS : Enrolls First Patient in Trial of FMX114 to Treat Atopic Dermatitis; S..
MT
10/19VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
PU
10/19VYNE THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
10/19VYNE THERAPEUTICS : Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of..
AQ
10/19VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment o..
CI
10/05VYNE THERAPEUTICS : Partner Cutia Therapeutics Enrolls First Patient in Late-Stage Acne Dr..
MT
More news
Analyst Recommendations on VYNE THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 18,2 M - -
Net income 2021 -70,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,01x
Yield 2021 -
Capitalization 69,5 M 69,5 M -
Capi. / Sales 2021 3,81x
Capi. / Sales 2022 9,69x
Nbr of Employees 106
Free-Float 87,2%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 1,35 $
Average target price 6,67 $
Spread / Average Target 394%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-78.64%70
JOHNSON & JOHNSON5.32%436 334
ROCHE HOLDING AG15.84%338 387
NOVO NORDISK A/S60.69%244 467
PFIZER, INC.17.22%244 227
ELI LILLY AND COMPANY47.15%225 231